MX2021013010A - Composiciones y metodos para modular la actividad del complemento. - Google Patents
Composiciones y metodos para modular la actividad del complemento.Info
- Publication number
- MX2021013010A MX2021013010A MX2021013010A MX2021013010A MX2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- sustained release
- release formulations
- complement activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Las modalidades de la divulgación proporcionan formulaciones de liberación sostenida que incluyen ingredientes activos y matrices moduladoras de la liberación. También se proporcionan métodos de preparación relacionados y métodos para abordar indicaciones terapéuticas con formulaciones de liberación sostenida descritas en el presente documento. Se incluyen formulaciones de liberación sostenida con inhibidores del complemento (por ejemplo, polipéptidos cíclicos inhibidores de C5, zilucoplan y/o metabolitos activos o variantes de los mismos) para tratar indicaciones relacionadas con el complemento.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962837978P | 2019-04-24 | 2019-04-24 | |
US201962947188P | 2019-12-12 | 2019-12-12 | |
US201962947183P | 2019-12-12 | 2019-12-12 | |
PCT/US2020/029733 WO2020219822A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for modulating complement activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013010A true MX2021013010A (es) | 2022-01-18 |
Family
ID=70977557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013010A MX2021013010A (es) | 2019-04-24 | 2020-04-24 | Composiciones y metodos para modular la actividad del complemento. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220211799A1 (es) |
EP (1) | EP3958842A1 (es) |
JP (1) | JP2022530042A (es) |
KR (1) | KR20220004039A (es) |
CN (1) | CN113710230A (es) |
AU (1) | AU2020261059A1 (es) |
BR (1) | BR112021017820A2 (es) |
CA (1) | CA3137895A1 (es) |
IL (1) | IL287079A (es) |
MX (1) | MX2021013010A (es) |
SG (1) | SG11202109837SA (es) |
TW (1) | TW202106290A (es) |
WO (1) | WO2020219822A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211561T8 (hr) | 2014-06-12 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulacija aktivnosti komplementa |
PT3250230T (pt) | 2015-01-28 | 2021-12-07 | Ra Pharmaceuticals Inc | Moduladores da atividade do complemento |
WO2017105939A1 (en) | 2015-12-16 | 2017-06-22 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1705100A (en) | 1998-10-09 | 2000-05-01 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
ES2522525T3 (es) | 2003-05-15 | 2014-11-14 | Genentech, Inc. | Métodos y composiciones para la prevención y el tratamiento de la sepsis |
CN1289066C (zh) * | 2003-09-18 | 2006-12-13 | 中国人民解放军第二军医大学 | 胰高血糖素样肽-1缓释微球制剂及其用途 |
CA2610502A1 (en) | 2005-03-29 | 2006-10-05 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
CN101227924A (zh) | 2005-05-26 | 2008-07-23 | 科罗拉多大学评议会 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
JP2009514888A (ja) | 2005-11-04 | 2009-04-09 | ジェネンテック・インコーポレーテッド | 眼疾患を処置するための補体経路の阻害剤の使用 |
HUE026042T2 (en) | 2006-10-10 | 2016-05-30 | Regenesance B V | Complement inhibition for improved nerve regeneration |
US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
BRPI0811007A2 (pt) | 2007-04-30 | 2015-01-27 | Alcon Res Ltd | Tratamento de degeneração macular relacionada à idade usando inibidores de fator de complemento d |
BRPI0812767A2 (pt) | 2007-06-07 | 2014-12-02 | Genentech Inc | Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento |
US20110142837A1 (en) | 2007-07-20 | 2011-06-16 | Trustees Of The University Of Pennsylvania | Method Of Treating Acute Respiratory Distress Syndrome |
US20110172126A1 (en) | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
US20100086596A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for releasing an octreotide compound without an initial time lag |
KR20110094029A (ko) | 2008-11-10 | 2011-08-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체-관련된 장애를 치료하는 방법 및 조성물 |
CA2971474C (en) | 2009-10-16 | 2022-11-22 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
US9358266B2 (en) | 2010-02-25 | 2016-06-07 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
ES2894342T3 (es) | 2011-04-08 | 2022-02-14 | Univ Leicester | Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2 |
WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
WO2014078622A1 (en) | 2012-11-15 | 2014-05-22 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
US20160324798A1 (en) * | 2013-12-31 | 2016-11-10 | Heron Therapeutics, Inc. | Polymer-based compositions for extended release of proteins |
HRP20211561T8 (hr) | 2014-06-12 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulacija aktivnosti komplementa |
WO2016138520A1 (en) | 2015-02-27 | 2016-09-01 | The Johns Hopkins University | Assay to diagnose and treat disorders of the alternative pathway of complement activation |
WO2017105939A1 (en) * | 2015-12-16 | 2017-06-22 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
EP4272821A3 (en) * | 2017-04-03 | 2024-01-03 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
-
2020
- 2020-04-24 JP JP2021562971A patent/JP2022530042A/ja active Pending
- 2020-04-24 KR KR1020217034548A patent/KR20220004039A/ko unknown
- 2020-04-24 CA CA3137895A patent/CA3137895A1/en active Pending
- 2020-04-24 SG SG11202109837S patent/SG11202109837SA/en unknown
- 2020-04-24 AU AU2020261059A patent/AU2020261059A1/en not_active Abandoned
- 2020-04-24 WO PCT/US2020/029733 patent/WO2020219822A1/en active Application Filing
- 2020-04-24 CN CN202080030772.3A patent/CN113710230A/zh active Pending
- 2020-04-24 US US17/605,495 patent/US20220211799A1/en active Pending
- 2020-04-24 BR BR112021017820A patent/BR112021017820A2/pt not_active Application Discontinuation
- 2020-04-24 TW TW109113822A patent/TW202106290A/zh unknown
- 2020-04-24 MX MX2021013010A patent/MX2021013010A/es unknown
- 2020-04-24 EP EP20730497.3A patent/EP3958842A1/en active Pending
-
2021
- 2021-10-07 IL IL287079A patent/IL287079A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022530042A (ja) | 2022-06-27 |
BR112021017820A2 (pt) | 2022-02-08 |
IL287079A (en) | 2021-12-01 |
CA3137895A1 (en) | 2020-10-29 |
TW202106290A (zh) | 2021-02-16 |
AU2020261059A1 (en) | 2021-10-14 |
US20220211799A1 (en) | 2022-07-07 |
KR20220004039A (ko) | 2022-01-11 |
EP3958842A1 (en) | 2022-03-02 |
SG11202109837SA (en) | 2021-10-28 |
CN113710230A (zh) | 2021-11-26 |
WO2020219822A1 (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013010A (es) | Composiciones y metodos para modular la actividad del complemento. | |
JOP20220130A1 (ar) | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم | |
MX2020003351A (es) | Metodos, composiciones y elementos implantables que comprenden celulas activas. | |
MX2022001874A (es) | Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. | |
BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
BR0314356A (pt) | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas | |
MX2010002712A (es) | Compuestos que modulan calcio intracelular. | |
MY157445A (en) | Compounds that modulate intracellular calcium. | |
MX2020013085A (es) | Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos. | |
WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
WO2020086747A3 (en) | Ssao inhibitors and uses thereof | |
MX2023009685A (es) | Inhibidores de tyk2 y sus usos. | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
JOP20190262B1 (ar) | مثبطات بيرازول magl | |
EP3819298A4 (en) | COMPOSITION WITH TRKA INHIBITIVE EFFECT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR RELIEF OF PAIN THEREOF AS AN ACTIVE SUBSTANCE | |
MX2021007948A (es) | Inhibidores de proteina de activacion de fibroblastos. | |
MX2023009723A (es) | Inhibidores de tyk2 y sus usos. | |
CR20220355A (es) | Compuestos activos frente a receptores nucleares | |
EP3915991A4 (en) | PYRROLOPYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE RELATED DISEASE COMPRISING IT AS ACTIVE INGREDIENT | |
MX2021013602A (es) | Inhibidores de jak. | |
MX2023001236A (es) | Inhibidores de cinasa inducibles por sal. | |
MX2020010834A (es) | Formulacion solida de mezclas insecticidas. | |
MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
MX2022000712A (es) | Moduladores de nlrp3. | |
EP3964520A4 (en) | NEW OLIGOPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IT AS AN ACTIVE SUBSTANCE |